拉贝洛尔在高血压患者中的药代动力学和药效学研究。
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.
作者信息
McNeil J J, Anderson A E, Louis W J, Morgan D J
出版信息
Br J Clin Pharmacol. 1979;8(Suppl 2):157S-161S.
Abstract
1 The pharmacokinetics of labetalol were studied in twelve hypertensive patients, ten of whom were not receiving other therapy. 2 Following intravenous administration there was a three- to fourfold variation in terminal elimination half-life, volume of distribution and total plasma clearance. The mean elimination half-life was 3.25 hours. 3 Following oral administration the drug was absorbed rapidly. Systemic availability varied from 11-86% (mean 33%). 4 Plasma levels correlated poorly with the acute effect on BP, raising the possibility of labetalol acting in a deep tissue compartment or alternatively an active metabolite contributing to its effect.
摘要
- 对12名高血压患者进行了拉贝洛尔的药代动力学研究，其中10名未接受其他治疗。2. 静脉给药后，终末消除半衰期、分布容积和总血浆清除率有三到四倍的差异。平均消除半衰期为3.25小时。3. 口服给药后，药物吸收迅速。全身可用性在11%-86%之间变化（平均33%）。4. 血浆水平与对血压的急性作用相关性较差，这增加了拉贝洛尔在深部组织隔室起作用的可能性，或者有一种活性代谢物对其作用有贡献。
相似文献
1
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.拉贝洛尔在高血压患者中的药代动力学和药效学研究。
Br J Clin Pharmacol. 1979;8(Suppl 2):157S-161S.
2
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.
Br J Clin Pharmacol. 1979 Apr;8 Suppl 2:157S-61S. doi: 10.1111/j.1365-2125.1979.tb04773.x.
3
Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.静脉注射拉贝洛尔治疗系统性动脉高血压的急性效应。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):805-8.
4
Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.接受抗高血压治疗患者中拉贝洛尔的平均稳态血浆浓度。
Br J Clin Pharmacol. 1979;8(Suppl 2):153S-155S.
5
The use of labetalol as a moderate hypotensive agent in otological operations--plasma concentrations after intravenous administration.
Int J Clin Pharmacol Ther Toxicol. 1980;18(5):191-4.
6
Pharmacokinetics of labetalol in healthy volunteers.拉贝洛尔在健康志愿者体内的药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1981 Jan;19(1):41-4.
7
Use of labetalol and methyldopa in pregnancy-induced hypertension.拉贝洛尔和甲基多巴在妊娠期高血压中的应用。
Br J Clin Pharmacol. 1979;8(Suppl 2):217S-222S.
8
Haemodynamic effects of long-term oral labetalol.长期口服拉贝洛尔的血流动力学效应。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):733-6.
9
Labetalol steady-state pharmacokinetics in hypertensive patients.高血压患者中拉贝洛尔的稳态药代动力学
Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):75S-80S. doi: 10.1111/j.1365-2125.1982.tb01892.x.
10
[Antihypertensive effects of labetalol administered parenterally and orally].静脉注射与口服拉贝洛尔的降压作用
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1984 Sep-Oct;36(5):405-12.
引用本文的文献
1
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.体外治疗β-肾上腺素能拮抗剂中毒：EXTRIP 工作组的系统评价和建议。
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
2
Measuring effects of medication adherence on time-varying health outcomes using Bayesian dynamic linear models.使用贝叶斯动态线性模型测量药物依从性对时变健康结果的影响。
Biostatistics. 2021 Jul 17;22(3):662-683. doi: 10.1093/biostatistics/kxz059.
3
Pseudopheochromocytoma.假性嗜铬细胞瘤。
Endocrinol Metab Clin North Am. 2019 Dec;48(4):751-764. doi: 10.1016/j.ecl.2019.08.004. Epub 2019 Sep 18.
4
Pseudopheochromocytoma Associated with Domestic Assault.与家庭暴力相关的假性嗜铬细胞瘤
Case Rep Cardiol. 2016;2016:6580215. doi: 10.1155/2016/6580215. Epub 2016 Sep 21.
5
Labetalol Prevents Intestinal Dysfunction Induced by Traumatic Brain Injury.拉贝洛尔可预防创伤性脑损伤所致的肠道功能障碍。
PLoS One. 2015 Jul 17;10(7):e0133215. doi: 10.1371/journal.pone.0133215. eCollection 2015.
6
Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.美托洛尔和拉贝洛尔在大鼠、小鼠和 Caco-2 细胞中的渗透性比较：作为 BCS 分类的参考标准。
Mol Pharm. 2013 Mar 4;10(3):958-66. doi: 10.1021/mp300410n. Epub 2013 Feb 4.
7
Drug therapy for resistant hypertension: simplifying the approach.耐药性高血压的药物治疗：简化治疗方法。
J Clin Hypertens (Greenwich). 2011 Feb;13(2):120-30. doi: 10.1111/j.1751-7176.2010.00387.x. Epub 2010 Nov 8.
8
Severe paroxysmal hypertension (pseudopheochromocytoma).重度阵发性高血压（假性嗜铬细胞瘤）
Curr Hypertens Rep. 2008 Feb;10(1):12-8. doi: 10.1007/s11906-008-0005-2.
9
Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension.联合α/β受体阻滞剂：一种治疗顽固性高血压但未得到充分应用的方法。
J Clin Hypertens (Greenwich). 2007 Sep;9(9):663-6. doi: 10.1111/j.1524-6175.2007.07225.x.
10
Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.联合α和β肾上腺素能受体阻滞剂（拉贝洛尔）对妊娠期高血压的循环和代谢影响
Br J Clin Pharmacol. 1981 Sep;12(3):345-8. doi: 10.1111/j.1365-2125.1981.tb01224.x.
本文引用的文献
1
Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.通过静脉输注后获得的输注后血药浓度曲线评估药代动力学常数。
J Pharm Sci. 1970 Jan;59(1):53-5. doi: 10.1002/jps.2600590107.
2
Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.AH 5158的药理学；一种能阻断α和β肾上腺素能受体的药物。
Br J Pharmacol. 1972 Aug;45(4):660-75. doi: 10.1111/j.1476-5381.1972.tb08125.x.
3
Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.α和β肾上腺素能受体拮抗剂AH5158A的临床研究
Br J Pharmacol. 1972 Feb;44(2):286-93. doi: 10.1111/j.1476-5381.1972.tb07265.x.
4
Metabolism of labetalol by animals and man.拉贝洛尔在动物和人体内的代谢。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):695-710.
5
Decreased first-pass metabolism of labetalol in chronic liver disease.慢性肝病中拉贝洛尔首过代谢降低。
Br Med J. 1978 Oct 14;2(6144):1048-50. doi: 10.1136/bmj.2.6144.1048.
6
Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.拉贝洛尔：在顽固性高血压急性和慢性治疗中的生物利用度、药物血浆水平、血浆肾素和儿茶酚胺
Aust N Z J Med. 1978 Dec;8(6):602-9. doi: 10.1111/j.1445-5994.1978.tb04847.x.
7
Relationship between plasma concentrations and pharmacological effects of labetalol.
Eur J Clin Pharmacol. 1977 Jan 3;11(2):85-90. doi: 10.1007/BF00562897.
8
Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):729-32.
Zotero 插件